Histone Deacetylase Inhibitor MC1293 Induces Latent HIV-1 Reactivation by Histone Modification In Vitro Latency Cell Lines

Author(s): Xiying Qu, Hao Ying, Xiaohui Wang, Chuijin Kong, Xin Zhou, Pengfei Wang, Huanzhang Zhu.

Journal Name: Current HIV Research

Volume 11 , Issue 1 , 2013

Become EABM
Become Reviewer


HIV-1 latency remains a major problem for the eradication of viruses in infected individuals. We evaluated the effect of MC1293 on the epigenetic change at HIV-1 LTR and the induction of the latent viruses in the latency Jurkat T cell line. We found MC1293 can activate HIV-1 gene expression, increase the acetylation level of H3 and H4 at the nuc-1 site of HIV-1 LTR. In addition, MC1293 can synergize with prostratin to activate the HIV-1 promoter, and has relatively lower toxicity compared to Trichostatin A (TSA). The results suggest that the acetylation of histone plays an important role in regulating HIV-1 LTR gene expression, and MC1293 is potential drug candidate for antilatency therapies.

Keywords: HIV-1 latency, MC1293, histone deacetylase inhibitors, histone modification, HDAC, drugs, patients, LTR, induction, viruses

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [24 - 29]
Pages: 6
DOI: 10.2174/1570162X11311010004

Article Metrics

PDF: 26